Nemera: Designing around the patient
Nemera combines rapid prototyping, laboratory testing and patient input to develop drug delivery devices that can move from an early need to industrial production.
A platform for new therapies
PenVario is Nemera's next-generation disposable, variable-dose pen injector. It is designed as a platform that can be adapted for a range of therapies, including diabetes. Devices like this can take years to develop, yet millions of people may eventually rely on them in daily life.
Nemera starts by turning ideas into tangible prototypes as early as possible. The team can then test how a concept fits a market need, refine it and assess performance in the laboratory before moving toward industrialization.
Two routes to innovation
The company develops devices in two ways. It can create a product for a customer, who owns the resulting design. It also develops its own intellectual property, known as Own-IP products.
Own-IP platforms give customers a developed starting point rather than a blank sheet. They accounted for 36 percent of device sales in 2024, up from 18 percent in 2018. Over the same growth period, Nemera expanded its customer base from around 200 in fiscal 2019 to more than 300 in 2024.
Patient input at scale
Nemera's teams use the principle of putting patients first to guide development. They consider the patient's voice, usability and the way a person will feel and interact with the device at each stage.
This approach links technical performance with the experience of the people who use the product. It also reflects what we look for in healthcare businesses: critical products, specialized expertise and innovation grounded in patient needs.
Nemera X Astorg
- The company employs around 3,000 people across seven manufacturing facilities and two innovation centers.
- Since Astorg began partnering with Nemera in 2019, the company has expanded both its capabilities and its international reach.
- Three acquisitions added early-stage development expertise in the US, parenteral-device capabilities in Poland and a manufacturing presence in Brazil.
- This has helped Nemera offer customers a more integrated path from initial device strategy and patient-centered design to industrial-scale manufacturing.
- Overall equipment effectiveness for injection processes increased from 74 percent in 2019 to 86 percent by February 2025, while the cost of non-quality fell by 40 percent over the same period.
Watch the video
This combination of patient-centered design and industrial execution supports the continued development of new Own-IP platforms, including new pen devices.
